Premium
Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum IV Prodrug Against Triple Negative Breast Cancer
Author(s) -
Muhammad Nafees,
CaiPing Tan,
Nasreen Sadia,
Mao ZongWan
Publication year - 2021
Publication title -
chemistry – an asian journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.18
H-Index - 106
eISSN - 1861-471X
pISSN - 1861-4728
DOI - 10.1002/asia.202100593
Subject(s) - triple negative breast cancer , prodrug , cisplatin , doxorubicin , mitochondrion , cancer research , breast cancer , chemistry , cancer cell , platinum , dna damage , apoptosis , cancer , chemotherapy , biology , medicine , biochemistry , dna , catalysis
A mitochondria targeting dual‐action platinum IV prodrug exhibits high anticancer activity in triple negative breast cancer cells. The complex intervenes in several cellular processes including DNA damage, perturbation of mitochondrial bioenergetics and induction of necrosis to kill cancer cells.